Member Info for EarlofAim

Drizzle have you seen FCM

gap to fill at 8p

All time low

distress seller out now

#FCM 2 days of solid buys. Should continue and tick up today. Huge gap to 8p to fill 📈

#FCM 2 days of solid buys. Should continue and tick up today. Huge gap to 8p to fill 📈

Sellers out and Oversold, news pending on zigzag

this has to be next big riser next week

Mk2 He1

IMO

GLA and Dyor before its too late

Sellers out and Oversold, news pending on zigzag

this has to be next big riser next week

Mk2 He1

IMO

GLA and Dyor before its too late

Hi Davy50

sorry to hear you lost 60%

not many saw this coming.

anyone thinks Aeg has a chance to recover from this?

Wise owl

matd traded last year

this year its IMM time

This is on another level

RE: LUPOZUR too big to fail......

LUPOZUR and by #imm @ImmuPharma

global sales team will around $1 Billion per year

Mcap only £6m

why has Avion spending £25m on Phase 3 trial

Dizzy gone dizzy heights

are you OK Dizzy,

Question why are Avion spending £25M on LUPOZUR phase 3?

so they can make billions?

and aim investors thinks they know better

Lordloadsoffolly

so you know more than Avion who are spending $25m on LUPOZUR phase 3

I suggest you take off your negative glasses off and look through the positive glass

This is on another level

RE: LUPOZUR too big to fail......

LUPOZUR and by #imm @ImmuPharma

global sales team will around $1 Billion per year

Mcap only £6m

why has Avion spending £25m on Phase 3 trial??

RE: LUPOZUR too big to fail......Today 10:58

LUPOZUR

global sales team will around $1 Billion per year

Mcap only £6m

why has Avion spending £25m on Phase 3 trial??

Avion funding seems they know LUPOZUR is game changing drugs for autoimmune therapy

Lanstead putting people off, however I reckon Lanstead will wait longer because of the huge news coming.

LUPOZUR

global sales team will around $1 Billion per year

Mcap only £6m

why has Avion spending £25m on Phase 3 trial??

Worldwide nothing like this in the market

Avion funding phase 3 Lupus trial for $25m the market is valuing this currently at around £5m…There isn’t a company globally that has a phase 3 trial fully funded in a multi billion $ market with double digit royalties and £70m milestones

Looks good for next week

Incanthera holding worth £1m alone, Avion funding phase 3 Lupus trial for $25m the market is valuing this currently at around £5m…There isn’t a company globally that has a phase 3 trial fully funded in a multi billion $ market with double digit royalties and £70m milestones

GLA and Dyor before its too late

Can IMM @ImmuPharma create similar buzz next week?

worth a look #imm some good research posted on twitter.

apparently $1Billion sales for its LUPOZUR should it get FDA approved,

currently phase 3

Sliced and add this....... IMM for this reason

Incanthera holding worth £1m alone, Avion funding phase 3 Lupus trial for $25m the market is valuing this currently at around £5m…There isn’t a company globally that has a phase 3 trial fully funded in a multi billion $ market with double digit royalties and £70m milestones

let HE1 profits come here and Sp does 100%

Incanthera holding worth £1m alone, Avion funding phase 3 Lupus trial for $25m the market is valuing this currently at around £5m…There isn’t a company globally that has a phase 3 trial fully funded in a multi billion $ market with double digit royalties and £70m milestones

let HE1 profits come here and Sp does 100%

Incanthera holding worth £1m alone, Avion funding phase 3 Lupus trial for $25m the market is valuing this currently at around £5m…There isn’t a company globally that has a phase 3 trial fully funded in a multi billion $ market with double digit royalties and £70m milestones